Insider Selling: Catalent, Inc. (NYSE:CTLT) Insider Sells $119,580.18 in Stock

Catalent, Inc. (NYSE:CTLT) insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Catalent Stock Up 0.1 %

NYSE CTLT opened at $60.33 on Monday. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. Catalent, Inc. has a 1 year low of $31.80 and a 1 year high of $61.20. The stock has a market capitalization of $10.92 billion, a PE ratio of -9.89, a PEG ratio of 2.32 and a beta of 1.15. The business’s 50-day moving average is $59.69 and its 200 day moving average is $57.34.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The business had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.23 billion. Sell-side analysts forecast that Catalent, Inc. will post 0.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CTLT shares. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. StockNews.com assumed coverage on Catalent in a research report on Thursday. They set a “sell” rating for the company. Barclays boosted their price objective on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. Robert W. Baird reiterated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating and eight have issued a hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $59.83.

Institutional Investors Weigh In On Catalent

A number of large investors have recently added to or reduced their stakes in the stock. Gamco Investors INC. ET AL raised its position in shares of Catalent by 403.3% during the first quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock valued at $1,428,000 after buying an additional 20,273 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Catalent by 2,792.9% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock worth $29,150,000 after buying an additional 498,540 shares during the period. UniSuper Management Pty Ltd raised its holdings in Catalent by 509.4% in the first quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company’s stock worth $1,028,000 after purchasing an additional 15,217 shares in the last quarter. Swedbank AB purchased a new stake in Catalent during the first quarter valued at approximately $1,659,000. Finally, SG Americas Securities LLC increased its position in Catalent by 147.4% during the 1st quarter. SG Americas Securities LLC now owns 99,588 shares of the company’s stock valued at $5,622,000 after buying an additional 59,339 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.